Literature DB >> 23231961

Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease.

Arianne van Koppen1, Jaap A Joles, Lennart G Bongartz, Jens van den Brandt, Holger M Reichardt, Roel Goldschmeding, Tri Q Nguyen, Marianne C Verhaar.   

Abstract

Chronic kidney disease (CKD) is a major health care problem. New interventions to slow or prevent disease progression are urgently needed. We studied functional and structural effects of infusion of healthy and CKD bone marrow cells (BMCs) in a rat model of established CKD. CKD was induced by 5/6 nephrectomy (SNX) in Lewis rats, and disease progression was accelerated with L-NNA and 6% NaCl diet. Six weeks after SNX, CKD rats received healthy eGFP(+) BMCs, CKD eGFP(+) BMCs, or vehicle by single renal artery injection. Healthy BMCs were functionally effective 6 weeks after administration: glomerular filtration rate (GFR; inulin clearance) (0.48±0.16 vs. 0.26±0.14 ml/min/100 g) and effective renal plasma flow (RPF; PAH clearance) (1.6±0.40 vs. 1.0±0.62 ml/min/100 g) were higher in healthy BMC- versus vehicle-treated rats (both p < 0.05). Systolic blood pressure (SBP) and proteinuria were lower 5 weeks after treatment with healthy BMCs versus vehicle (SBP, 151±13 vs. 186±25 mmHg; proteinuria, 33±20 vs. 59±39 mg/day, both p < 0.05). Glomerular capillary density was increased, and less sclerosis was detected after healthy BMCs (both p < 0.05). Tubulointerstitial inflammation was also decreased after healthy BMCs. eGFP(+) cells were present in the glomeruli and peritubular capillaries of the remnant kidney in all BMC-treated rats. CKD BMCs also reduced SBP, proteinuria, glomerulosclerosis, and tubular atrophy versus vehicle in CKD rats. However, CKD BMC therapy was not functionally effective versus vehicle [GFR: 0.28±0.09 vs. 0.26±0.16 ml/min/100 g (NS), RPF: 1.15±0.36 vs. 0.78±0.44 ml/min/100 g (NS)], and failed to decrease tubulointerstitial inflammation and fibrosis. Single intrarenal injection of healthy BMCs in rats with established CKD slowed progression of the disease, associated with increased glomerular capillary density and less sclerosis, whereas injection of CKD BMCs was less effective.

Entities:  

Mesh:

Year:  2012        PMID: 23231961     DOI: 10.3727/096368912X636795

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  20 in total

Review 1.  A perspective on chronic kidney disease progression.

Authors:  Jianyong Zhong; Hai-Chun Yang; Agnes B Fogo
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-14

Review 2.  Challenges and opportunities for stem cell therapy in patients with chronic kidney disease.

Authors:  LaTonya J Hickson; Alfonso Eirin; Lilach O Lerman
Journal:  Kidney Int       Date:  2016-01-26       Impact factor: 10.612

3.  Low white blood cell count is independently associated with chronic kidney disease progression in the elderly: the CKD-ROUTE study.

Authors:  Yohei Arai; Eiichiro Kanda; Soichiro Iimori; Shotaro Naito; Yumi Noda; Sei Sasaki; Eisei Sohara; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2017-07-11       Impact factor: 2.801

4.  5/6th nephrectomy in combination with high salt diet and nitric oxide synthase inhibition to induce chronic kidney disease in the Lewis rat.

Authors:  Arianne van Koppen; Marianne C Verhaar; Lennart G Bongartz; Jaap A Joles
Journal:  J Vis Exp       Date:  2013-07-03       Impact factor: 1.355

Review 5.  The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.

Authors:  Tao Yang; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Nat Rev Nephrol       Date:  2018-07       Impact factor: 28.314

6.  Apparent Correlations Between AMPK Expression and Brain Inflammatory Response and Neurological Function Factors in Rats with Chronic Renal Failure.

Authors:  Li Yang; Ni-Rong Gong; Qin Zhang; Ya-Bin Ma; Hui Zhou
Journal:  J Mol Neurosci       Date:  2019-03-27       Impact factor: 3.444

7.  Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease.

Authors:  Arianne van Koppen; Jaap A Joles; Bas W M van Balkom; Sai Kiang Lim; Dominique de Kleijn; Rachel H Giles; Marianne C Verhaar
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

Review 8.  Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis.

Authors:  Diana A Papazova; Nynke R Oosterhuis; Hendrik Gremmels; Arianne van Koppen; Jaap A Joles; Marianne C Verhaar
Journal:  Dis Model Mech       Date:  2015-01-29       Impact factor: 5.758

9.  Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.

Authors:  Arianne van Koppen; Diana A Papazova; Nynke R Oosterhuis; Hendrik Gremmels; Rachel H Giles; Joost O Fledderus; Jaap A Joles; Marianne C Verhaar
Journal:  Stem Cell Res Ther       Date:  2015-04-15       Impact factor: 6.832

10.  Ex vivo manipulation of bone marrow cells to rescue uremia-induced dysfunction for autologous therapy.

Authors:  Cristina Grange; Benedetta Bussolati
Journal:  Stem Cell Res Ther       Date:  2015-06-11       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.